Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
r-etodolac
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
R-etodolac (SDX-101) is the R-enantiomer of the nonsteroidal anti-inflammatory drug (NSAID) etodolac. Unlike the S-enantiomer, which is responsible for cyclooxygenase (COX) inhibition and associated anti-inflammatory effects, R-etodolac is a non-COX-inhibiting compound that exhibits potent pro-apoptotic and antitumor activity. Its mechanism of action involves binding to the Retinoid X Receptor (RXR) and downregulating the Wnt/beta-catenin signaling pathway, as well as modulating PPAR-gamma activity. This leads to the selective induction of apoptosis in malignant cells, particularly in B-cell chronic lymphocytic leukemia (B-CLL) and multiple myeloma. Developed by Salmedix (later acquired by Cephalon), R-etodolac was designed to provide a safer therapeutic profile by avoiding the gastrointestinal and renal toxicities typically associated with traditional NSAIDs.
- Brand names
- SDX-101SDX101SDX 101
- Other names
- (R)-etodolac
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)RXRA (Retinoid X receptor alpha)
Beyond the preview
Go deeper on r-etodolac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on r-etodolac.